JOP20180088A1 - Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide - Google Patents
Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamideInfo
- Publication number
- JOP20180088A1 JOP20180088A1 JOP/2018/0088A JOP20180088A JOP20180088A1 JO P20180088 A1 JOP20180088 A1 JO P20180088A1 JO P20180088 A JOP20180088 A JO P20180088A JO P20180088 A1 JOP20180088 A1 JO P20180088A1
- Authority
- JO
- Jordan
- Prior art keywords
- hydroxypyrrolidine
- pyrazolo
- difluorophenyl
- pyrrolidin
- pyrimidin
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A liquid formulation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JOP/2018/0088A JOP20180088B1 (en) | 2018-10-02 | 2018-10-02 | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JOP/2018/0088A JOP20180088B1 (en) | 2018-10-02 | 2018-10-02 | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Publications (2)
Publication Number | Publication Date |
---|---|
JOP20180088A1 true JOP20180088A1 (en) | 2020-04-02 |
JOP20180088B1 JOP20180088B1 (en) | 2023-09-17 |
Family
ID=75469090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2018/0088A JOP20180088B1 (en) | 2018-10-02 | 2018-10-02 | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Country Status (1)
Country | Link |
---|---|
JO (1) | JOP20180088B1 (en) |
-
2018
- 2018-10-02 JO JOP/2018/0088A patent/JOP20180088B1/en active
Also Published As
Publication number | Publication date |
---|---|
JOP20180088B1 (en) | 2023-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502124A1 (en) | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | |
PH12021550809A1 (en) | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | |
PH12018502134A1 (en) | Methods of treating pediatric cancers | |
PH12020500028A1 (en) | Crystalline forms of a bruton`s tyrosine kinase inhibitor | |
MX2021015408A (en) | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor. | |
MX2021004546A (en) | Implantable drug delivery compositions and methods of use thereof. | |
MX2017012430A (en) | Solvated forms of a bruton's tyrosine kinase inhibitor. | |
MX2021010058A (en) | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders. | |
TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
JOP20180088B1 (en) | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | |
TWI799923B (en) | Use of thioimidazolidinone drugs in the treatment of covid-19 disease | |
WO2007010337A3 (en) | Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors | |
MX2022015438A (en) | Dispersible tablet formulations comprising dolutegravir. | |
MX2019000159A (en) | Substituted pyrrolo [2, 3-d] pyridazin-4-ones and pyrazolo [3, 4-d] pyridazin-4-ones as protein kinase inhibitors. | |
AR108090A1 (en) | LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PIRROLIDIN-1-IL) -PIRAZOLO [1,5-A] PIRIMIDIN-3-IL) -3 -HYDROXIPIRROLIDINA-1-CARBOXAMIDA | |
JOP20180089A1 (en) | ): methods of treating pediatric cancers | |
TW202423443A (en) | Pharmaceutical formulations of nintedanib for intraocular use |